Wedbush Keeps a Buy Rating on Intercept Pharma (ICPT)

By Ryan Adsit

Wedbush analyst Liana Moussatos reiterated a Buy rating on Intercept Pharma (ICPTResearch Report) today and set a price target of $243.00. The company’s shares closed last Monday at $75.25.

According to TipRanks.com, Moussatos is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -10.5% and a 34.8% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Catabasis Pharmaceuticals, Global Blood Therapeutics, and Eiger Biopharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Intercept Pharma with a $148.27 average price target, a 99.7% upside from current levels. In a report released today, Needham also maintained a Buy rating on the stock with a $150.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $131.87 and a one-year low of $56.76. Currently, Intercept Pharma has an average volume of 480K.

Based on the recent corporate insider activity of 100 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ICPT in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Intercept Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline is OCALIVA which is used for the treatment of primary biliary cholangitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in New York, NY.